Efficacy of ω-3 supplementation in patients with psoriasis: a meta-analysis of randomized controlled trials

Cain Clark, Mohsen Taghizadeh, Mina Nahavandi, Sadegh Jafarnejad

Research output: Contribution to journalReview article

Abstract

Several studies have been conducted with the aim of investigating the effect of Omega(ω)-3 on different psoriasis indices including Psoriasis Area and Severity Index (PASI) score, erythema, scaling, itching, area involved, and infiltration. Nevertheless, a pooled analysis of trials that evaluated these variables has not been conducted. Therefore, the aim of this meta-analysis was to assess the efficacy of ω-3 fatty acids in treating patients with psoriasis. We searched through different electronic, references of retrieved articles, and previous related reviews databases up to November 2018. Both combined and stratified analyzes were conducted. A fixed-effects or random effects model was used to assess the mean effect sizes. An eventual 10 studies involving 560 participants were considered as eligible for inclusion in the present meta-analysis. The meta-analysis indicated a significant reduction in PASI score by − 1.58 (95% confidence interval (CI), − 2.24, − 0.92; P < 0.001) in favor of ω-3 polyunsaturated fatty acid (PUFA) group. The random effects model showed a statistically significant beneficial effect of ω-3 PUFA supplementation on reducing erythema by − 1.66 unit and reducing scaling (weighted mean difference (WMD), − 0.69; 95% CI, − 1.26, − 0.13; P = 0.02). Significant improvements in erythema, itching, and scale were observed in the trials which used the higher dosage of ω-3 supplementation. The results of current meta-analysis study support the use of ω-3 PUFA supplementation for the improvement of the evaluated parameters in psoriatic patients. However, well-controlled and randomized studies are needed to confirm the veracity of non-significant and/or equivocal findings.

LanguageEnglish
Pages977-988
Number of pages12
JournalClinical Rheumatology
Volume38
Issue number4
Early online date18 Feb 2019
DOIs
Publication statusPublished - Apr 2019

Fingerprint

Omega-3 Fatty Acids
Psoriasis
Meta-Analysis
Erythema
Randomized Controlled Trials
Unsaturated Fatty Acids
Pruritus
Confidence Intervals
Databases

Keywords

  • Meta-analysis
  • Polyunsaturated fatty acids
  • Psoriasis
  • PUFA

ASJC Scopus subject areas

  • Rheumatology

Cite this

Efficacy of ω-3 supplementation in patients with psoriasis : a meta-analysis of randomized controlled trials. / Clark, Cain; Taghizadeh, Mohsen ; Nahavandi, Mina ; Jafarnejad, Sadegh .

In: Clinical Rheumatology, Vol. 38, No. 4, 04.2019, p. 977-988.

Research output: Contribution to journalReview article

Clark, Cain ; Taghizadeh, Mohsen ; Nahavandi, Mina ; Jafarnejad, Sadegh . / Efficacy of ω-3 supplementation in patients with psoriasis : a meta-analysis of randomized controlled trials. In: Clinical Rheumatology. 2019 ; Vol. 38, No. 4. pp. 977-988.
@article{38375e072adf4aee978b33074b5f69fb,
title = "Efficacy of ω-3 supplementation in patients with psoriasis: a meta-analysis of randomized controlled trials",
abstract = "Several studies have been conducted with the aim of investigating the effect of Omega(ω)-3 on different psoriasis indices including Psoriasis Area and Severity Index (PASI) score, erythema, scaling, itching, area involved, and infiltration. Nevertheless, a pooled analysis of trials that evaluated these variables has not been conducted. Therefore, the aim of this meta-analysis was to assess the efficacy of ω-3 fatty acids in treating patients with psoriasis. We searched through different electronic, references of retrieved articles, and previous related reviews databases up to November 2018. Both combined and stratified analyzes were conducted. A fixed-effects or random effects model was used to assess the mean effect sizes. An eventual 10 studies involving 560 participants were considered as eligible for inclusion in the present meta-analysis. The meta-analysis indicated a significant reduction in PASI score by − 1.58 (95{\%} confidence interval (CI), − 2.24, − 0.92; P < 0.001) in favor of ω-3 polyunsaturated fatty acid (PUFA) group. The random effects model showed a statistically significant beneficial effect of ω-3 PUFA supplementation on reducing erythema by − 1.66 unit and reducing scaling (weighted mean difference (WMD), − 0.69; 95{\%} CI, − 1.26, − 0.13; P = 0.02). Significant improvements in erythema, itching, and scale were observed in the trials which used the higher dosage of ω-3 supplementation. The results of current meta-analysis study support the use of ω-3 PUFA supplementation for the improvement of the evaluated parameters in psoriatic patients. However, well-controlled and randomized studies are needed to confirm the veracity of non-significant and/or equivocal findings.",
keywords = "Meta-analysis, Polyunsaturated fatty acids, Psoriasis, PUFA",
author = "Cain Clark and Mohsen Taghizadeh and Mina Nahavandi and Sadegh Jafarnejad",
year = "2019",
month = "4",
doi = "10.1007/s10067-019-04456-x",
language = "English",
volume = "38",
pages = "977--988",
journal = "Clinical Rheumatology",
issn = "0770-3198",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Efficacy of ω-3 supplementation in patients with psoriasis

T2 - Clinical Rheumatology

AU - Clark, Cain

AU - Taghizadeh, Mohsen

AU - Nahavandi, Mina

AU - Jafarnejad, Sadegh

PY - 2019/4

Y1 - 2019/4

N2 - Several studies have been conducted with the aim of investigating the effect of Omega(ω)-3 on different psoriasis indices including Psoriasis Area and Severity Index (PASI) score, erythema, scaling, itching, area involved, and infiltration. Nevertheless, a pooled analysis of trials that evaluated these variables has not been conducted. Therefore, the aim of this meta-analysis was to assess the efficacy of ω-3 fatty acids in treating patients with psoriasis. We searched through different electronic, references of retrieved articles, and previous related reviews databases up to November 2018. Both combined and stratified analyzes were conducted. A fixed-effects or random effects model was used to assess the mean effect sizes. An eventual 10 studies involving 560 participants were considered as eligible for inclusion in the present meta-analysis. The meta-analysis indicated a significant reduction in PASI score by − 1.58 (95% confidence interval (CI), − 2.24, − 0.92; P < 0.001) in favor of ω-3 polyunsaturated fatty acid (PUFA) group. The random effects model showed a statistically significant beneficial effect of ω-3 PUFA supplementation on reducing erythema by − 1.66 unit and reducing scaling (weighted mean difference (WMD), − 0.69; 95% CI, − 1.26, − 0.13; P = 0.02). Significant improvements in erythema, itching, and scale were observed in the trials which used the higher dosage of ω-3 supplementation. The results of current meta-analysis study support the use of ω-3 PUFA supplementation for the improvement of the evaluated parameters in psoriatic patients. However, well-controlled and randomized studies are needed to confirm the veracity of non-significant and/or equivocal findings.

AB - Several studies have been conducted with the aim of investigating the effect of Omega(ω)-3 on different psoriasis indices including Psoriasis Area and Severity Index (PASI) score, erythema, scaling, itching, area involved, and infiltration. Nevertheless, a pooled analysis of trials that evaluated these variables has not been conducted. Therefore, the aim of this meta-analysis was to assess the efficacy of ω-3 fatty acids in treating patients with psoriasis. We searched through different electronic, references of retrieved articles, and previous related reviews databases up to November 2018. Both combined and stratified analyzes were conducted. A fixed-effects or random effects model was used to assess the mean effect sizes. An eventual 10 studies involving 560 participants were considered as eligible for inclusion in the present meta-analysis. The meta-analysis indicated a significant reduction in PASI score by − 1.58 (95% confidence interval (CI), − 2.24, − 0.92; P < 0.001) in favor of ω-3 polyunsaturated fatty acid (PUFA) group. The random effects model showed a statistically significant beneficial effect of ω-3 PUFA supplementation on reducing erythema by − 1.66 unit and reducing scaling (weighted mean difference (WMD), − 0.69; 95% CI, − 1.26, − 0.13; P = 0.02). Significant improvements in erythema, itching, and scale were observed in the trials which used the higher dosage of ω-3 supplementation. The results of current meta-analysis study support the use of ω-3 PUFA supplementation for the improvement of the evaluated parameters in psoriatic patients. However, well-controlled and randomized studies are needed to confirm the veracity of non-significant and/or equivocal findings.

KW - Meta-analysis

KW - Polyunsaturated fatty acids

KW - Psoriasis

KW - PUFA

UR - http://www.scopus.com/inward/record.url?scp=85061697516&partnerID=8YFLogxK

U2 - 10.1007/s10067-019-04456-x

DO - 10.1007/s10067-019-04456-x

M3 - Review article

VL - 38

SP - 977

EP - 988

JO - Clinical Rheumatology

JF - Clinical Rheumatology

SN - 0770-3198

IS - 4

ER -